A combination treatment of immunotherapy with the experimental drug guadecitabine may reverse a cancer’s resistance to immunotherapy – making it sensitive to treatment again, a new study has found.

Artificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to new research.

A new type of immunotherapy making use of the immune system’s ‘natural killer cells’ could offer potential against a range of cancers that can evade current treatments, early results from a phase I trial suggest.